4010 completed, 375 terminated, 158 recruiting, 150 withdrawn. 1398 Phase 1, 1267 Phase 2, 1100 Phase 3, 539 Phase 4, 209 Not applicable.
By phase and status
Phase Trials Status Phase 1 1398 Completed 1140 , Terminated 118 , Withdrawn 49 , Recruiting 37 , Active not recruiting 32 , Not yet recruiting 14 , Unknown 7 , Suspended 1 Phase 2 1267 Completed 937 , Terminated 146 , Recruiting 61 , Active not recruiting 47 , Withdrawn 47 , Unknown 16 , Not yet recruiting 13 Phase 3 1100 Completed 928 , Terminated 64 , Recruiting 46 , Active not recruiting 22 , Withdrawn 21 , Unknown 12 , Not yet recruiting 7 Phase 4 539 Completed 449 , Terminated 36 , Unknown 20 , Withdrawn 17 , Active not recruiting 7 , Not yet recruiting 5 , Recruiting 4 , Enrolling by invitation 1 Not applicable 209 Completed 171 , Terminated 14 , Unknown 13 , Withdrawn 6 , Recruiting 3 , Not yet recruiting 1 , Suspended 1 Early Phase 1 16 Completed 10 , Active not recruiting 2 , Recruiting 2 , Terminated 2
Follow GlaxoSmithKline: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus Phase 2 Not yet recruiting 12 2027-02-01 2026-09-28
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial Phase 1 Not yet recruiting 60 2027-01-25 2026-07-16
A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303) Ris-Rez, Atezolizumab, Etoposide - Lung Neoplasm Phase 3 Not yet recruiting 700 2026-12-25 2026-11-18
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer Dostarlimab - Neoplasms, Rectal Phase 3 Not yet recruiting 100 2026-12-17 2026-11-16
B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants Bepirovirsen - Hepatitis B Phase 4 Not yet recruiting 303 2026-12-03 2026-11-02
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) Phase 1 Not yet recruiting 108 2026-12-01 2026-09-21
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma Phase 3 Recruiting 500 2026-12-01 2026-11-12
A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors RZV vaccine, Placebo - Cardiovascular Disease Phase 3 Not yet recruiting 16390 2026-11-30 2026-10-13
A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours GSK5864399 - Solid Tumours Phase 1 / Phase 2 Not yet recruiting 155 2026-11-25 2026-11-18
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial Phase 3 Not yet recruiting 378 2026-11-12 2026-10-19
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms Phase 1 Not yet recruiting 40 2026-11-10 2026-10-06
A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants Bepirovirsen - Hepatitis B Phase 1 Not yet recruiting 98 2026-11-03 2026-10-29
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) Phase 4 Not yet recruiting 268 2026-11-01 2026-09-17
A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) GSK3862995B, GSK5784283, Placebo - Pulmonary Disease, Chronic Obstructive Phase 2 Recruiting 279 2026-10-29 2026-11-17
A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib Velzatinib - Healthy Participants, Gastrointestinal Neoplasms Phase 1 Not yet recruiting 30 2026-10-23 2026-10-09
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma Phase 1 Not yet recruiting 20 2026-10-23 2026-05-27
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events Placebo, Adjuvanted RZV vaccine, Adjuvanted RSVPreF3 vaccine - Cardiovascular Disease Phase 2 Not yet recruiting 450 2026-10-23 2026-10-20
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20) - Multiple Myeloma Phase 1 Not yet recruiting 22 2026-10-16 2026-08-03
A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants Velzatinib, Cyclosporine, Omeprazole - Healthy Participants, Gastrointestinal Neoplasms Phase 1 Not yet recruiting 36 2026-10-16 2026-10-07
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) Velzatinib - Gastrointestinal Neoplasms Phase 2 Not yet recruiting 72 2026-10-13 2026-09-28
Showing 20 of 4953. Sign in to see all of them.
Conditions studied Pulmonary Disease, Chronic Obstructive (339) · Asthma (314) · Influenza, Human (200) · Neoplasms (166) · Hepatitis B (152) · Diabetes Mellitus, Type 2 (151) · Infections (146) · Acquired Immunodeficiency Syndrome (133) · HIV Infections (130) · Breast Neoplasms (106) · Tetanus (103) · Diphtheria (98) · Haemophilus Infections (83) · Meningococcal Infections (78) · Papillomavirus Infections (72)
Interventions Lapatinib (115) · Fluticasone (112) · pazopanib (92) · fluticasone furoate (71) · Rosiglitazone (64) · Data Collection (62) · Fluticasone-Salmeterol Drug Combination (62) · belimumab (60) · dostarlimab (60) · Topotecan (58) · mepolizumab (58) · dolutegravir (57) · Blood Specimen Collection (55) · Salmeterol Xinafoate (54) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (54)
Countries United States (2122) · United Kingdom (819) · Germany (720) · Canada (627) · Spain (519) · France (451) · Australia (414) · Italy (379) · Belgium (376) · South Korea (347) · Japan (343) · Netherlands (335) · Poland (317) · Russia (299) · Argentina (249)
Top investigators Roger K Cady, MD (6) · Anthony Greco, MD (4) · Christian Tielemans, MD, PhD (3) · David V Condoluci, DO (3) · Evangelos Terpos, Prof (3)
Results publications PMID 41276263 , PMID 25387217 , PMID 36005278 , PMID 27881132 , PMID 36472162 , PMID 24314123 , PMID 34628605 , PMID 34741731 , PMID 37781954 , PMID 26704701 , PMID 28683300 , PMID 30954640 , PMID 32710245 , PMID 34473343 , PMID 34531304 , PMID 38775637 , PMID 38780109 , PMID 39115551 , PMID 39208825 , PMID 20526599 , PMID 24408395 , PMID 24443277 , PMID 24918790 , PMID 26446943 , PMID 31824976 , PMID 33687069 , PMID 34098955 , PMID 34523118 , PMID 38216728 , PMID 38724182 , PMID 39377226 , PMID 40190112 , PMID 41461999 , PMID 23054212 , PMID 23254770 , PMID 24731816 , PMID 24966061 , PMID 24998880 , PMID 25424785 , PMID 25424918 , PMID 26873055 , PMID 27093773 , PMID 27796912 , PMID 29465480 , PMID 31047111 , PMID 31164116 , PMID 31197640 , PMID 31251094 , PMID 31302695 , PMID 31321713
NIH funding 2016 (55) , 2017 (51) , 2023 (48) , 2015 (41) , 2025 (36) , 2014 (31) , 2018 (24) , 2009 (22) , 2008 (18) , 2019 (14) , 2004 (8) , 2005 (7) , K23HD045386 (2) , P30CA138292 (2) , U01AI065683 (2)